BioCryst [BCRX] vs Zoetis [ZTS] Detailed Stock Comparison
BioCryst
NASDAQ
Loading...
Zoetis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: BioCryst wins in 8 metrics, Zoetis wins in 11 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | BioCryst | Zoetis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -16.63 | 25.16 | BioCryst |
| Price-to-Book Ratio | -3.55 | 13.06 | BioCryst |
| Debt-to-Equity Ratio | -1.75 | 137.01 | BioCryst |
| PEG Ratio | 0.12 | 1.44 | BioCryst |
| EV/EBITDA | 33.84 | 17.80 | Zoetis |
| Profit Margin (TTM) | -6.41% | 27.83% | Zoetis |
| Operating Margin (TTM) | 18.23% | 40.20% | Zoetis |
| EBITDA Margin (TTM) | 18.23% | 40.20% | Zoetis |
| Return on Equity | 18.68% | 52.77% | Zoetis |
| Return on Assets (TTM) | 7.46% | 15.37% | Zoetis |
| Free Cash Flow (TTM) | $-53.14M | $2.30B | Zoetis |
| Dividend Yield | N/A | 1.11% | N/A |
| 1-Year Return | -5.52% | -22.95% | BioCryst |
| Price-to-Sales Ratio (TTM) | 2.69 | 6.91 | BioCryst |
| Enterprise Value | $1.98B | $70.26B | Zoetis |
| EV/Revenue Ratio | 3.55 | 7.49 | BioCryst |
| Gross Profit Margin (TTM) | 98.29% | 73.62% | BioCryst |
| Revenue per Share (TTM) | $3 | $21 | Zoetis |
| Earnings per Share (Diluted) | $-0.18 | $5.82 | Zoetis |
| Beta (Stock Volatility) | 1.05 | 0.90 | Zoetis |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
BioCryst vs Zoetis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| BioCryst | -1.82% | -7.02% | -14.29% | -19.86% | 3.39% | -10.34% |
| Zoetis | 1.51% | 2.03% | -3.94% | -8.02% | -8.26% | -9.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| BioCryst | -5.52% | -48.12% | 82.34% | -20.59% | 39.84% | -58.09% |
| Zoetis | -22.95% | -0.64% | -11.49% | 242.10% | 372.17% | 372.17% |
News Based Sentiment: BioCryst vs Zoetis
BioCryst
News based Sentiment: POSITIVE
BioCryst's strategic sale of its European business and subsequent debt reduction are significant developments that position the company for stronger financial performance and focused growth in the U.S. market. While an 'In-Line' rating and oversold territory suggest caution, the overall narrative is positive due to the proactive steps taken by management.
Zoetis
News based Sentiment: MIXED
The month featured both positive developments – the CVMP opinion for Portela® and generally positive analyst estimates – alongside negative signals like stock decline, technical warnings, and mixed institutional activity. This creates a balanced, rather than decisively positive or negative, investment narrative.
Performance & Financial Health Analysis: BioCryst vs Zoetis
| Metric | BCRX | ZTS |
|---|---|---|
| Market Information | ||
| Market Cap | $1.55B | $65.09B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,671,443 | 3,169,830 |
| 90 Day Avg. Volume | 2,651,864 | 2,720,843 |
| Last Close | $7.02 | $167.10 |
| 52 Week Range | $6.02 - $11.31 | $139.70 - $200.33 |
| % from 52W High | -37.93% | -16.59% |
| All-Time High | $37.25 (Mar 06, 2000) | $249.27 (Dec 27, 2021) |
| % from All-Time High | -81.15% | -32.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.49% | 0.04% |
| Quarterly Earnings Growth | 0.49% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | -0.06% | 0.28% |
| Operating Margin (TTM) | 0.18% | 0.40% |
| Return on Equity (TTM) | 0.19% | 0.53% |
| Debt to Equity (MRQ) | -1.75 | 137.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.01 | $11.21 |
| Cash per Share (MRQ) | $1.24 | $3.28 |
| Operating Cash Flow (TTM) | $16.82M | $2.93B |
| Levered Free Cash Flow (TTM) | $53.98M | $2.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.11% |
| Last 12-Month Dividend | N/A | $1.86 |
Valuation & Enterprise Metrics Analysis: BioCryst vs Zoetis
| Metric | BCRX | ZTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -16.63 | 25.16 |
| Forward P/E | -178.75 | 23.09 |
| PEG Ratio | 0.12 | 1.44 |
| Price to Sales (TTM) | 2.69 | 6.91 |
| Price to Book (MRQ) | -3.55 | 13.06 |
| Market Capitalization | ||
| Market Capitalization | $1.55B | $65.09B |
| Enterprise Value | $1.98B | $70.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.55 | 7.49 |
| Enterprise to EBITDA | 33.84 | 17.80 |
| Risk & Other Metrics | ||
| Beta | 1.05 | 0.90 |
| Book Value per Share (MRQ) | $-2.01 | $11.21 |
Financial Statements Comparison: BioCryst vs Zoetis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BCRX | ZTS |
|---|---|---|
| Revenue/Sales | $145.53M | $2.22B |
| Cost of Goods Sold | $4.57M | $622.00M |
| Gross Profit | $140.97M | $1.60B |
| Research & Development | $37.27M | $157.00M |
| Operating Income (EBIT) | $21.23M | $846.00M |
| EBITDA | $24.58M | $991.00M |
| Pre-Tax Income | $758,000 | $810.00M |
| Income Tax | $726,000 | $179.00M |
| Net Income (Profit) | $32,000 | $631.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BCRX | ZTS |
|---|---|---|
| Cash & Equivalents | $105.19M | $1.72B |
| Total Current Assets | $409.98M | $5.88B |
| Total Current Liabilities | $139.86M | $3.39B |
| Long-Term Debt | $792.12M | $5.40B |
| Total Shareholders Equity | $-451.93M | $4.66B |
| Retained Earnings | $-1.77B | $12.38B |
| Property, Plant & Equipment | $19.58M | $6.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BCRX | ZTS |
|---|---|---|
| Operating Cash Flow | $21.14M | $567.00M |
| Capital Expenditures | $-143,000 | N/A |
| Free Cash Flow | $-27.66M | $438.00M |
| Debt Repayment | $-516,000 | N/A |
| Common Stock Repurchase | N/A | $-443.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BCRX | ZTS |
|---|---|---|
| Shares Short | 28.32M | 9.19M |
| Short Ratio | 12.15 | 3.71 |
| Short % of Float | 0.14% | 0.02% |
| Average Daily Volume (10 Day) | 2,671,443 | 3,169,830 |
| Average Daily Volume (90 Day) | 2,651,864 | 2,720,843 |
| Shares Outstanding | 208.54M | 448.47M |
| Float Shares | 195.52M | 442.31M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 0.99% | 0.99% |
Dividend Analysis & Yield Comparison: BioCryst vs Zoetis
| Metric | BCRX | ZTS |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.86 |
| Last 12-Month Dividend Yield | N/A | 1.11% |
| 3-Year Avg Annual Dividend | N/A | $1.63 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $4.90 |
| Ex-Dividend Date | N/A | Apr 21, 2025 |